Levetiracetam Actavis

Levetiracetam, the active ingredient in Levetiracetam Actavis, is an anticonvulsant presented as an oral tablet for oral use. It is prescribed to manage various seizure types in patients with epilepsy. The medication works by modulating neuronal activity, helping to control abnormal electrical discharges in the brain.

GNH USA supplies Levetiracetam Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our global distribution network ensures reliable access to quality‑assured medicines across diverse markets while adhering to stringent regulatory standards to maintain product integrity.

Levetiracetam is used to treat epilepsy by targeting seizure activity across several seizure categories.

Partial‑onset seizures: reduces seizure frequency in patients with focal epilepsy. Generalized tonic‑clonic seizures: helps prevent convulsive episodes in generalized epilepsy. Myoclonic seizures: decreases myoclonic jerks in patients with juvenile myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Irritability: mood changes or increased agitation. - Nausea: upset stomach with possible vomiting. - Weight gain: increase in body weight over time.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Psychiatric symptoms: depression, suicidal thoughts, or severe anxiety. - Blood disorders: low platelet count or neutropenia. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Liver injury: jaundice or elevated liver enzymes.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal function: adjust dose in patients with impaired kidney function. - Pregnancy: evaluate risk‑benefit as safety data are limited. - Psychiatric history: monitor for mood changes or suicidal ideation. - Concomitant CNS depressants: use caution as additive sedation may occur. - Alcohol use: advise patients to limit intake due to potential increased drowsiness. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing effectiveness. - Phenobarbital: can lower levetiracetam concentrations, risking breakthrough seizures. - Phenytoin: may decrease levetiracetam exposure, requiring close monitoring.

Moderate Interactions (Monitor Closely): - Alcohol: can enhance central nervous system depression, increasing drowsiness. - Other antiepileptics (e.g., valproate): may require dose adjustments based on therapeutic monitoring. - Contraceptive steroids: potential reduction in hormonal efficacy, advise alternative contraception.